67P Real-world outcomes for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab
ConclusionThis real-world study of nivolumab in R/M SCCHN patients in the United States shows that the improved survival demonstrated by nivolumab in CheckMate 141 translates into similar real-world outcomes for patients, with an even greater benefit in first-line patients. These results are consistent with other observational analyses in Europe and reinforce the survival benefit of nivolumab in R/M SCCHN patients as early as first line.Legal entity responsible for the studyBristol-Myers Squibb.FundingBristol-Myers Squibb.DisclosureP. Singh: Full / Part-time employment: Bristol-Myers Squibb. M. You: Full / Part-time employment: Bristol-Myers Squibb. S. Lubinga: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb. Y. Zhang: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Employment | Head and Neck Cancer | Legislation | Oropharyngeal Cancer | Skin Cancer | Smokers | Squamous Cell Carcinoma | Study | USA Health